Compare · LUCY vs RXST
LUCY vs RXST
Side-by-side comparison of Innovative Eyewear Inc. (LUCY) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCY and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- RXST is the larger of the two at $194.2M, about 26.5x LUCY ($7.3M).
- LUCY has been more active in the news (6 items in the past 4 weeks vs 1 for RXST).
- RXST has more recent analyst coverage (25 ratings vs 0 for LUCY).
- Company
- Innovative Eyewear Inc.
- RxSight Inc.
- Price
- $0.81-4.08%
- $4.51-3.22%
- Market cap
- $7.3M
- $194.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2021
- News (4w)
- 6
- 1
- Recent ratings
- 0
- 25
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest LUCY
- SEC Form 8-K filed by Innovative Eyewear Inc.
- SEC Form 8-K filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Launches Lucyd Aero
- Innovative Eyewear Reports Record Preliminary Q3 2026 Net Sales, Up 55% Year-Over-Year
- SEC Form DEF 14A filed by Innovative Eyewear Inc.
- SEC Form PRE 14A filed by Innovative Eyewear Inc.
- Innovative Eyewear, Inc. Announces Exclusive Australia and New Zealand Distribution Partnership with Directed Electronics
- Innovative Eyewear, Inc. Announces Q3 Business Update
- Chief Financial Officer Gayle Oswald was granted 32,466 shares and sold $13,491 worth of shares (15,533 units at $0.87), increasing direct ownership by 591% to 19,798 units (SEC Form 4)
- Chief AI & Growth Officer Dabrowski Konrad sold $11,874 worth of shares (13,627 units at $0.87) and was granted 41,800 shares, increasing direct ownership by 220% to 40,977 units (SEC Form 4)
Latest RXST
- K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
- Officer Weinberg Eric exercised 35,168 shares at a strike of $4.34, increasing direct ownership by 18% to 235,516 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Wilterding Mark
- SEC Form 4 filed by Officer Weinberg Eric
- SEC Form 4 filed by Chief Medical Officer Kurtz Ronald M Md
- SEC Form 4 filed by Chief Operating Officer Goldshleger Ilya
- Amendment: SEC Form SC TO-I/A filed by RxSight Inc.
- Chief Medical Officer Kurtz Ronald M Md converted options into 13,425 shares and sold $35,496 worth of shares (5,100 units at $6.96), increasing direct ownership by 13% to 71,775 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Wilterding Mark converted options into 20,441 shares and sold $54,044 worth of shares (7,765 units at $6.96), increasing direct ownership by 102% to 25,049 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Goldshleger Ilya converted options into 5,370 shares and sold $14,205 worth of shares (2,041 units at $6.96), increasing direct ownership by 4% to 81,509 units (SEC Form 4) (tax withholding)